Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · Real-Time Price · USD
6.82
+0.12 (1.79%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.

The company’s lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma.

It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia.

Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals logo
CountryUnited States
Founded2018
IndustryBiotechnology
SectorHealthcare
Employees5
CEOMichael Myers

Contact Details

Address:
42127 Pleasant Forest Court
Ashburn, Virginia 20148-7349
United States
Phone703 980 4182
Websitequoinpharma.com

Stock Details

Ticker SymbolQNRX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001671502
CUSIP Number74907L102
ISIN NumberUS74907L3006
SIC Code2834

Key Executives

NamePosition
Dr. Michael Myers Ph.D.Co-Founder, Chief Executive Officer and Chairman
Denise CarterCo-Founder, Chief Operating Officer and Director
Gordon Bruce Dunn J.D.Chief Financial Officer

Latest SEC Filings

DateTypeTitle
Jul 17, 2025ARSFiling
Jul 17, 2025DEF 14AOther definitive proxy statements
Jul 8, 20258-KCurrent Report
Jul 7, 2025PRE 14AOther preliminary proxy statements
Jun 25, 20258-KCurrent Report
Jun 20, 20258-KCurrent Report
Jun 4, 20258-KCurrent Report
May 23, 20258-KCurrent Report
May 21, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling